The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis. | Zendy

A. Kaegi | Zendy; G F Pineo | Zendy; Akira Shimizu | Zendy; H.L. Trivedi | Zendy; J. Hirsh | Zendy; Michael Gent | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The role of sulfinpyrazone in the prevention of arterio-venous shunt thrombosis.

Author(s) -

A. Kaegi,

G F Pineo,

Akira Shimizu,

H.L. Trivedi,

J. Hirsh,

Michael Gent

Publication year - 1975

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.52.3.497

Subject(s) - medicine , sulfinpyrazone , thrombosis , crossover study , venous thrombosis , placebo , incidence (geometry) , cardiology , surgery , anesthesia , aspirin , physics , alternative medicine , pathology , optics

The effect of sulfinpyrazone on the incidence of thrombosis of arterio-venous shunts was investigated in a double-blind crossover study in 45 patients on chronic hemodialysis over a period of 12 months. The incidence of thrombosis was reduced from 0.64 thrombi per patient month when on placebo to 0.21 thrombi per patient month when on sulfinpryazone (P less than 0.001). The therapeutic effect was more striking in men than in women and became evident within a week of starting the drug. The side effects were minimal, requiring withdrawal from the study of only one patient. This crossover study strengthens the findings in the previous report that sulfinpyrazone is of value in the prevention of thrombosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research